Receptor News and Research

RSS

Virus-cell interaction may partly explain the higher infection rate of COVID-19

Bioengineering researchers at Lehigh University have identified a previously unknown interaction between receptors in human cells and the spike, or "S," protein of SARS-CoV-2, the virus that causes COVID-19.

29 Mar 2021

Single Sputnik V vaccine dose elicits robust immune response in previously infected individuals

A new preprint research paper posted to the medRxiv server describes successful immunization of the vaccinated population with a single dose of the Russian-made Sputnik V vaccine.

29 Mar 2021

First cell-based gene therapy approved by the FDA for treating multiple myeloma

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.

29 Mar 2021

Linear epitope mapping of the SARS-CoV-2 spike protein

The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been the primary target of many drug discovery efforts and is similarly utilized in each of the approved COVID-19 vaccines to elicit the generation of anti-spike protein antibodies, thereby granting immunity.

28 Mar 2021

Antibody agents effective at neutralizing European, South African, and United States SARS-CoV-2 variants

Researchers in the United States have demonstrated the effectiveness of three antibody agents at neutralizing recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic.

28 Mar 2021

New SARS-CoV-2 genome variants identified in US mink

Researchers in Canada have discovered two novel variants in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gene sequences collected from mink in the United States.

28 Mar 2021

mRNA vaccines and monoclonal antibodies protect against new NYC-B.1.526 variant

A new fast-spreading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant called B.1.526 recently emerged in New York City and caused concerns for its potential to resist the immune system.

28 Mar 2021

Selecting SARS-CoV-2 inhibitors in human airway epithelial cells

In a recent article currently available on the bioRxiv* preprint server, researchers from Belgium and the U.S. demonstrated a robust replication model for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates in primary human epithelial cells at the air-liquid interface and appraised the antiviral effect of selected viral replication inhibitors.

28 Mar 2021

Novel molecule could offer a new way to fight against SARS coronavirus 2

Scientists at the University of Bonn and the caesar research center have isolated a molecule that might open new avenues in the fight against SARS coronavirus 2. The active ingredient binds to the spike protein that the virus uses to dock to the cells it infects.

27 Mar 2021

Using molecular ‘cookie cutters’ to isolate first ever COVID-19 encounter complex

University of Birmingham researchers are working to isolate and extract the COVID-19 encounter complex in a form that is stable enough for identification of target sites for future anti-viral drugs.

27 Mar 2021

New study may shed light on inflammatory bowel disease

Researchers have found an unexpected synergy between a T-cell stimulatory protein -- the ICOS ligand -- and interleukin-10, an immunoregulatory cytokine, to prevent inflammatory bowel disease in mice.

26 Mar 2021

Moffitt researchers use mathematical modeling to help explain outcomes of CAR T-cell therapy

Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas.

25 Mar 2021

Scientists reveal salivary gland cells as sites of COVID-19 infection

Scientists have shown that SARS-CoV-2, the virus that causes COVID-19, can infect specific cells in the salivary gland in the mouth.

25 Mar 2021

Study identifies NCOA3 as a novel therapeutic target for melanoma

For the first time, activation of nuclear receptor coactivator 3 (NCOA3) has been shown to promote the development of melanoma through regulation of ultraviolet radiation (UVR) sensitivity, cell cycle progression and circumvention of the DNA damage response.

25 Mar 2021

Study observes correlation between COVID-19 mortality and autoantibodies in corticosteroid treated patients

Corticosteroid anti-inflammatory drugs have been applied to COVID-19 patients over the course of the pandemic, though the results are mixed. In a recent study, the outcomes for such patients are collated, demonstrating a striking correlation between the development of autoantibodies and mortality.

25 Mar 2021

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

A team of scientists from the USA and Canada recently characterized the cross-neutralizing potency of anti-SARS-CoV-2 antibodies isolated from COVID-19 patients. The findings reveal that some of the isolated antibodies targeting the spike RBD and the S2 subunit are capable of cross-neutralizing other members of the human beta-coronavirus family.

25 Mar 2021

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

The scientific consensus is that safe and highly effective vaccines are required to end the ongoing pandemic of coronavirus disease 2019 COVID-19, caused by SARS-CoV-2. A new study describes a new vaccine that presents two viral antigens to the human immune system, in order to elicit a more efficacious response.

25 Mar 2021

Receptor News and Research

Virus-cell interaction may partly explain the higher infection rate of COVID-19

Single Sputnik V vaccine dose elicits robust immune response in previously infected individuals

First cell-based gene therapy approved by the FDA for treating multiple myeloma

Linear epitope mapping of the SARS-CoV-2 spike protein

Antibody agents effective at neutralizing European, South African, and United States SARS-CoV-2 variants

New SARS-CoV-2 genome variants identified in US mink

mRNA vaccines and monoclonal antibodies protect against new NYC-B.1.526 variant

Selecting SARS-CoV-2 inhibitors in human airway epithelial cells

Novel molecule could offer a new way to fight against SARS coronavirus 2

Using molecular ‘cookie cutters’ to isolate first ever COVID-19 encounter complex

New study may shed light on inflammatory bowel disease

Moffitt researchers use mathematical modeling to help explain outcomes of CAR T-cell therapy

Scientists reveal salivary gland cells as sites of COVID-19 infection

Study identifies NCOA3 as a novel therapeutic target for melanoma

Study observes correlation between COVID-19 mortality and autoantibodies in corticosteroid treated patients

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

Researchers find evidence that SARS-CoV-2 infects cells in the mouth

Researcher to use new approach to explore brain proteins and their potential to cure mental diseases

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News